Catalys Pacific, LLC

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 12, 2024), Catalys Pacific, LLC reported 3 stock positions worth $125.4 million. Its top holding was Mineralys Therapeutics (MLYS) at 83.5% of the portfolio, followed by Phathom Pharmaceuticals (PHAT, 16.2%) and Hillevax (HLVX, 0.3%). Compared with Q2 2024, it added to 1 and reduced 2. The biggest buy was Phathom Pharmaceuticals (PHAT, shares +55%) and the biggest sale Hillevax (HLVX, shares −80%).

Most Recent 13F
Q2 2026
Location
TOKYO, M0
CIK
0002011385
Portfolio Value
$125.4M (Q3 2024)
SEC Filing
0001104659-24-116643 ↗ filed Nov 12, 2024

Holdings Value

0$100.0M$200.0M$300.0M$400.0M Q1 2024: $148.1M Q1 2024 Q2 2024: $132.5M Q2 2024 Q3 2024: $125.4M $125.4M Q3 2024 Q4 2024: $115.9M Q4 2024 Q1 2025: $148.7M Q1 2025 Q2 2025: $131.7M Q2 2025 Q3 2025: $351.4M Q3 2025 Q4 2025: $310.5M Q4 2025 Q1 2026: $230.7M Q1 2026 Q2 2026: $229.5M Q2 2026

Holdings 3 stocks · $125.4M
MLYS Mineralys Therapeutics Inc. 83.48% 8,644,579 $104.7M Reduce -6.0%
PHAT Phathom Pharmaceuticals Inc. 16.19% 1,122,572 $20.3M Add +55.5%
HLVX Hillevax Inc. 0.33% 236,379 $416K Reduce -80.5%

Portfolio Sells Q2 2024 → Q3 2024
HLVX Hillevax Inc. Reduce -80.5% 0.33% −12.86
MLYS Mineralys Therapeutics Inc. Reduce -6.0% 83.48% +2.29

Portfolio Buys Q2 2024 → Q3 2024
PHAT Phathom Pharmaceuticals Inc. Add +55.5% 16.19% +10.57

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$229.5MMLYS, PHAT
Q1 2026 2$230.7MMLYS, PHAT
Q4 2025 2$310.5MMLYS, PHAT
Q3 2025 2$351.4MMLYS, PHAT
Q2 2025 2$131.7MMLYS, PHAT
Q1 2025Amended 2$148.7MMLYS, PHAT
Q4 2024 2$115.9MMLYS, PHAT
Q3 2024 3$125.4MMLYS, PHAT, HLVX
Q2 2024 3$132.5MMLYS, HLVX, PHAT
Q1 2024 3$148.1MMLYS, HLVX, PHAT